| 產(chǎn)品名稱 |
B7Ig |
| 商品貨號 |
B200424 |
| Designations |
B7Ig |
| GenBank Number |
M27286
M27533
X81695
Z17370
|
| Species |
Homo sapiens, human |
| Depositors |
Bristol-Myers Squibb Co., P Linsley, Bristol-Myers Squibb Co. |
| Applications |
in another host, produces protein CD80 antigen - IgCgamma1 chimera |
| Vector |
Construct size (kb): 5.400000095367432 |
| Insert |
DNA: cDNA Insert lengths(kb): 0.6800000071525574 Tissue: Burkitt's lymphoma Raji cell line Gene product: immunoglobulin gamma 1 (Gm marker)(immunoglobulin heavy chain constant region, gamma 1) [CD80] Target Gene: CD80 antigen - IgCgamma1 chimera |
| Insert Size (kb) |
0.680 |
| Media |
ATCC® Medium 1890: LB medium (ATCC medium 1065) with 12 mcg/ml tetracycline and 100 mcg/ml ampicillin
|
| Biosafety Level |
1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Shipping Information |
Distributed: freeze-dried |
| Comments |
Restriction digests of the clone give the following sizes (kb): HindIII/XbaI--3.9, 1.5; PstI--5.4; XhoI--5.4. The Ig hinge cysteines were mutated to serine residues during construction to prevent intrachain disulfide bonding. Expresses a soluble derivative of B7, consisting of the oncostatin M signal sequence, the extracellular portion of B7, and the hinge, CH2 and CH3 portions of Ig Cgamma1. |
| References |
Freeman GJ, et al. B7, a new member of the Ig superfamily with unique expression on activated and neoplastic B cells. J. Immunol. 143: 2714-2722, 1989. PubMed: 2794510
Linsley PS. Chimeric CTLA4 receptor and methods for its use. US Patent 5,434,131 dated Jul 18 1995
Linsley PS, et al. Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation. J. Exp. Med. 173: 721-730, 1991. PubMed: 1847722
|
| Disclosure |
This material is cited in a US or other Patent and may not be used to
infringe the claims. Depending on the wishes of the Depositor, ATCC may be
required to inform the Patent Depositor of the party to which the material was
furnished. This material may not have been produced or characterized by ATCC. |
